Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edgar Castillo

Psychiatry Fresno, CA Medical Doctor

NPI 1851492847 CMS profile 84464

30 E River Park Pl W, Suite # 310, Fresno, CA 93720

Open in the dashboard

General payments

$17,545

622 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edgar Castillo of Fresno, CA is reported in the CMS Open Payments database as having received $17,545 across 622 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,908 87
2024 General $3,329 93
2023 General $2,892 89
2022 General $2,218 99
2021 General $2,266 105
2020 General $775 45
2019 General $3,157 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edgar Castillo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Edgar Castillo were reported at $2,908. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Edgar Castillo Psychiatry median Middle half National median
2019 $3,157 $184 $59–$605 $163
2020 $775 $119 $36–$372 $114
2021 $2,266 $143 $43–$576 $132
2022 $2,218 $153 $50–$590 $149
2023 $2,892 $170 $56–$651 $160
2024 $3,329 $179 $57–$673 $164
2025 $2,908 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $3,459 109 payments
  2. ITI, Inc. $2,165 83 payments
  3. Alkermes, Inc. $1,727 59 payments
  4. AbbVie, Inc. $1,501 65 payments
  5. Vanda Pharmaceuticals Inc. $1,324 48 payments
  6. Teva Pharmaceuticals USA, Inc. $1,216 44 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $793 52 payments
  8. Janssen Pharmaceuticals, Inc $783 20 payments
  9. Axsome Therapeutics, Inc. $762 18 payments
  10. Neurocrine Biosciences, Inc. $698 12 payments
  11. Other $3,117 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,034 616 payments
  2. Education $311 5 payments
  3. Consulting Fee $200 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI $2,094 70 payments
  2. ABILIFY MAINTENA $1,595 46 payments
  3. VRAYLAR $1,395 59 payments
  4. CAPLYTA $1,385 63 payments
  5. FANAPT $1,324 48 payments
  6. LYBALVI $1,197 40 payments
  7. ARISTADA Cns $1,154 48 payments
  8. ARISTADA Cns $1,154 48 payments
  9. ARISTADA Cns $1,022 41 payments
  10. ARISTADA Cns $1,022 41 payments
  11. Other $11,491 392 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

384

Median for Psychiatry: 574

Drug cost

$95,883

Median for Psychiatry: $27,624

Branded share of claims

39.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 73 $50,706
Vraylar Cariprazine Hcl Brand 19 $27,461
Trintellix Vortioxetine Hydrobromide Brand 45 $14,650
Ziprasidone Hcl Generic 23 $966
Buspirone Hcl Generic 41 $807
Mirtazapine Generic 39 $291
Sertraline Hcl Generic 35 $167
Venlafaxine Hcl Er Venlafaxine Hcl Brand 13 $154
Hydroxyzine Hcl Generic 13 $146
Aripiprazole Generic 16 $140

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $377
  • Lundbeck LLC $94
$471 73 —
FANAPT
  • Vanda Pharmaceuticals Inc. $418
$418 — —
VRAYLAR
  • AbbVie, Inc. $394
$394 19 —
CAPLYTA
  • ITI, Inc. $345
$345 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $235
$235 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record